Quote Lookup

Please enter a ticker symbol below and click Submit.
Symbol:        VL Survey Page (2013-03-15)Premium Content

Exelixis Inc (EXEL)

2013-05-20@04:20:53 ET
Exelixis Q1 net loss increases (DTM)

2013-05-20@01:41:19 ET
Exelixis to Present at American Society of Clinical Oncology Annual Meeting (CLM)

2013-05-20@01:21:39 ET
Exelixis' Cabozantinib to be Featured at 2013 ASCO Annual Meeting (CLM)

2013-05-18@09:46:51 ET
Form 4: Update Filing for Exelixis Inc (EXEL) (VKR)

2013-05-18@09:46:41 ET
Form 4: Update Filing for Exelixis Inc (EXEL) (VKR)

2013-05-18@09:46:31 ET
Form 4: Update Filing for Exelixis Inc (EXEL) (VKR)

2013-05-18@09:46:21 ET
Form 4: Update Filing for Exelixis Inc (EXEL) (VKR)

2013-05-18@09:46:11 ET
Form 4: Update Filing for Exelixis Inc (EXEL) (VKR)

2013-05-18@09:46:01 ET
Form 4: Update Filing for Exelixis Inc (EXEL) (VKR)

2013-05-18@09:45:51 ET
Form 4: Update Filing for Exelixis Inc (EXEL) (VKR)

2013-05-18@09:45:41 ET
Form 4: Update Filing for Exelixis Inc (EXEL) (VKR)

2013-05-18@09:45:31 ET
Form 4: Update Filing for Exelixis Inc (EXEL) (VKR)

2013-05-18@09:45:21 ET
Form 4: Update Filing for Exelixis Inc (EXEL) (VKR)

2013-05-18@03:35:37 ET
Australia Patent: Exelixis Files Application for 'Methods of using MEK inhibitors' (ABW)

2013-05-15@16:02:00 ET
Reminder: Cabozantinib to be Featured in Nine Presentations at the 2013 ASCO Annual Meeting (BIZ)

2013-05-13@00:24:02 ET
Exelixis Releases 1Q 2013 Results (CLM)

2013-05-13@00:23:53 ET
Cabozantinib to Present at 2013 ASCO Annual Meeting (CLM)